Prognostic significance of Ki-67 antigen expression in non-Hodgkin's lymphomas

Anticancer Research

Volumn 28, Issue 2 A, 2008, Pages 1113-1118

  Szczuraszek, Katarzyna ^a   Mazur, Grzegorz ^a   Jeleń, Michał ^a   Dziȩgiel, Piotr ^a   Surowiak, Paweł ^a   Zabel, Maciej ^a,b  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Ki 67 antigen; Non Hodgkin's lymphoma; Prognosis

Indexed keywords

KI 67 ANTIGEN; PARAFFIN;

ANTIGEN EXPRESSION; ARTICLE; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; EVALUATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NONHODGKIN LYMPHOMA; PARAMETER; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL SIGNIFICANCE; SURVIVAL;

CELL PROLIFERATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 42549111153     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Skarin AT and Dorfman DM: Non-Hodgkin's lymphomas: current classification and management. CA-Cancer J Clinicians 47: 351-372, 1997.
2. Shipp MA, Harrington DP, Anderson JR and Armitage JO: A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329: 987, 1993.
3. Gerdes J: Ki-67 and other proliferation markers useful for immunohistologocal diagnostic and prognostic evaluations in human malignancies. Semin Cancer Biol 1: 199-206, 1990.
4. Hall PA, Richards MA, Gregory WM, d'Ardenne AJ, Lister TA and Stansfeld AG: The prognostic value of Ki-67 immunostaining in non-Hodgkin's lymphoma. J Pathol 154: 223-235, 1998.
5. Velders GA, Kluin-Nelemans JC, De Boer CJ, Hermans J, Noodijk EM, Schuuring E, Kramer Mh, Van Deijk WA, Rahder JB, Kluin PM and Van Krieken JH: Mantle-cell lymphoma: a population-based clinical study. J Clin Oncol 14(4): 1269-1274, 1996.
6. Kologeraki A, Tzardi M, Panagiotides I, Koutsoubi K, Bolioti S, Rontogianni D, Stefanaki K, Zois E, Karidi E, Darivianaki K, Delides G and Kanavaros P: MIB-1 (Ki-67) expression in non-Hodgkin's lymphomas. Anticancer Res 17(1A): 487-491, 1997.
7. Pastuszewski W, Dziegiel P, Krecicki T, Podhorska-Okolow M, Ciesielska U, Gorzynska E and Zabel M: Prognostic significance of metallothionein, p53 protein and Ki-67 antigen expression in larygeal cancer. Anticancer Res 27: 335-342, 2007.
8. Gryczynski M and Pastuszewska W: Selected aspects of apoptosis and cell proliferation in laryngeal carcinoma. Otolaryngologia 1: 151-160, 2002 (in Polish).
9. Szelachowska J, Dziegiel P, Jelen-Krzeszewska J, Jelen M, Matkowski R, Pomiecko A, Spytkowska B, Jagas M, Gisterek I and Kornafel J: Mcm-2 protein expression predicts prognostic better than Ki-67 antigen in oral squamocellular carcinoma. Anticancer Res 26: 2473-2478, 2006.
10. Dziegiel P and Zabel M: Role of immunohistochemical expression of Ki-67 in adenocarcinoma of large intestine. In: Immunohistochemistry and In Situ Hybridization of Human Carcinomas. Hayat MA (eds.). London, Elsevier Academic Press, pp. 127-134, 2006.
11. Brown DC and Gatter KC: Ki-67 protein: the immaculate deception? Histopathology 40: 2-11, 2002.
12. Scholzen T and Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol 182: 311-332, 2000.
13. Dziegiel P, Salwa-Zurawska W, Zurawski J, Wojnar A and Zabel M: Prognostic significance of augmented metallothionein (MT) expression corellated with Ki-67 antigen expression in selected soft tissue sarcomas. Histol Histopathol 20: 83-89, 2005.
14. Hennessy BT, Hanrahan EO and Daly PA: Non-Hodgkin Lymphoma: an update. Lancet Onkol 5: 341-353, 2004.
15. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred C, Clarc GM, Ruby SG, O'Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A and Schnitt SJ: Prognostic factors in breast cancer. Arch Pathol Lab Med 124: 7, 2000.
16. Aho R, Haapasalo H, Alanen K, Haltia M and Kalimo H: Proliferative activity and DNA index do not significantly predict survival in primary central nervous system lymphoma. J Neuropathol Exp Neurol 54(6): 826-832, 1995.
17. Tiemann M, Schrader C, Klapper W, Dreyling MH, Campo E, Norton A, Berger F, Kluin P, Ott G, Pileri S, Pedrinis E, Feller AC, Merz H, Janssen D, Hansmann ML, Krieken H, Moller P, Stein H, Unterhalt M, Hiddemann W and Parwaresch R: Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network. Br J Haematol 131: 29-38, 2005.
18. Martin AR, Weisenburger DD, Chan WC, Ruby EI, Anderson JR, Vose JM, Bierman PJ, Bast MA, Daley DT and Armitage JO: Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood 85: 3671-3678, 1995.
19. Gerdes J, Schwab U, Lemke H and Stein H: Production of mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31: 13-20, 1983.
20. Gerdes J, Dallenbach F, Lennert K, Lemke H and Stein H: Growth fractions in malignant non-Hodgkin's lymphomas (NHL) as determined in situ with the monoclonal antibody Ki-67. Hematol Oncol 2: 365-371, 1984.
21. Itami M, Takenouchi T, Tamatru J, Harigaya K and Mikata A: Expression of functional molecules in non-Hodgkin's lymphoma. Correlation with bone morrow involvement and serum LDH value. Acta Pathol Jpn 41(4): 277-285, 1991.
22. Tominaga k, Yamaguchi Y, Nozawa Y, Abe M and Wakasa H: Proliferation in non-Hodgkin's lymphomas as determined by immunohistochemical double staining for Ki-67. Hematol Oncol 10(3-4): 163-169, 1992.
23. Xu W, Sheng R, Zheng Z and Xu T: The expression and clinical significance of proliferative antigen Ki-67 and apoptosis-antagonizing antigen Bcl-2 in non-Hodgkin's lymphoma Zhonghua Nei Ke Za Zhi 40(7): 452-455, 2001 (in Chinese).
24. Roser F, Saini M, Meliss R, Ostertag H, Samii M and Bellinzona M: Apoptosis, vascularity, and proliferation in primary central nervous system lymphomas (PCNSL): a histopathological study. Surg Neurol 62(5): 393-399, 2004.
25. Brown DC and Gatter KC: Monoclonal antibody Ki-67: its use in histopathology. Histopathology 17: 489-503, 1990.
26. Pence J, Kerns B and Dodge R: Prognostic significance of the proliferation index in surgically resected non-small cell lung cancer. Arch Surg 128: 1382-1390, 1993.
27. Pugsley JM, Schmidt RA and Vesselle H: The Ki-67 index and survival in non-small cell lung cancer: a review and relevance to positron emission tomography. Cancer 8: 222-233, 2002.
28. Haerslev T, Jacobson GK and Zedeler K: Correlation of growth fraction by Ki-67 and proliferating cell nuclear antigen (PCNA) immunohistochemistry with histopathological parameters and prognosis in primary breast carcinomas. Breast Cancer Res Treat 37: 101-113, 1996.
29. Nakamura M, Konishi M, Tsunoda S, Nakase H, Tsuzuki T, Aoki H, Sakitani H, Inui T and Sakaki T: Analysis of prognostic and survival factors related to treatment of low-grade astrocytomas in adults. Oncology 58: 108-116, 2000.
30. Reitmaier M, Rudlowski C, Biesterfeld S, Rath W and Schroder W: Comparative studies on the biological significance of the marker for proliferation Ki-67-antigen and PCNA in primary ovarian carcinoma. Zentralbl Gynakol 122: 361-7, 2000 (in German).
31. Nylander K, Stenling R, Gustafsson R, Zackrisson B and Roos G: p53 Expression and cell proliferation in squamous cell carcinoma of the head and neck. Cancer 75: 87-93, 1995.
32. Spafford MF, Koeppe J, Pan Z, Archer PG, Meyers AD and Franklin WA: Correlation of tumour markers p53, bcl-2, CD34, CD44H, CD44v6 and Ki-67 with survival and metastasis in laryngeal squamous carcinoma. Arch Otolaryngol Head Neck Surg 122: 644-648, 1996.
33. Welkoborsky HJ, Hinni M, Dienes HP and Mann WJ: Predicting recurrence and survival in patients with laryngeal cancer by means of DNA cytometry, tumour front grading, and proliferation markers. Ann Otol Rhinol Laryngol 104: 503-510, 1995.